Background: Invasive candidiasis and candidemia are frequently encountered in the nosocomial setting particularly in the intensive care unit (ICU). Objective and methods: To review the current management of invasive candidiasis and candidemia in non-neutropenic adult ICU patients based on a review of the literature and an European expert panel discussion. Results and conclusions: Empiric and directed treatment for invasive candidiasis are predicated on the hemodynamic status of the patient. Unstable patients may benefit from broad-spectrum antifungal agents, which can be narrowed once the patient has stabilized and the identity of the infecting species is established. In stable patients, a more classical approach using fluconazole may be satisfactory provided that the patient is not colonized with fluconazole resistant strains or there has been recent past exposure to an azole (<30 days). In contrast, pre-emptive therapy is based on the presence of surrogate markers.
Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment / Benoît P., Guery; Maiken C., Arendrup; Georg, Auzinger; Elie, Azoulay; Marcio Borges, Sa; Elizabeth M., Johnson; Eckhard, Muller; Christian, Putensen; Coleman, Rotstein; Gabriele, Sganga; Venditti, Mario; Rafael Zaragoza, Crespo; Bart Jan, Kullberg. - In: INTENSIVE CARE MEDICINE. - ISSN 0342-4642. - STAMPA. - 35:2(2009), pp. 206-214. [10.1007/s00134-008-1339-6]
Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment
VENDITTI, Mario;
2009
Abstract
Background: Invasive candidiasis and candidemia are frequently encountered in the nosocomial setting particularly in the intensive care unit (ICU). Objective and methods: To review the current management of invasive candidiasis and candidemia in non-neutropenic adult ICU patients based on a review of the literature and an European expert panel discussion. Results and conclusions: Empiric and directed treatment for invasive candidiasis are predicated on the hemodynamic status of the patient. Unstable patients may benefit from broad-spectrum antifungal agents, which can be narrowed once the patient has stabilized and the identity of the infecting species is established. In stable patients, a more classical approach using fluconazole may be satisfactory provided that the patient is not colonized with fluconazole resistant strains or there has been recent past exposure to an azole (<30 days). In contrast, pre-emptive therapy is based on the presence of surrogate markers.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.